Mumbai: Emcure Pharmaceuticals Ltd. has announced an exclusive distribution and promotion partnership with Sanofi India Limited (SIL) for its portfolio of oral anti-diabetic drugs (OADs).
The agreement, effective immediately, marks a significant step in enhancing healthcare delivery for the country’s growing diabetic population.
Under the terms of the partnership, Emcure will exclusively promote and distribute Sanofi’s oral anti-diabetic drugs brands, including the widely prescribed Amaryl and Cetapin, throughout India.
Also Read: Piramal Pharma Solutions Launches USD 90M Expansion to Boost US Manufacturing
Sanofi will continue to own and manufacture these brands at its facilities in India and globally. There will be no employee transition from Sanofi to Emcure as part of this deal.
“Over 100 million Indians are currently living with type 2 diabetes, with more than 60% struggling to manage blood sugar levels,” said Eric Mansion, General Manager – Pharma Southeast Asia and India, Sanofi.
“This partnership with Emcure – known for its strong pan-India reach – will ensure that our best-in-class oral anti-diabetic drugs reach more patients and doctors, driving better diabetes management outcomes.”
With diabetes emerging as one of India’s most pressing health challenges, this collaboration is set to improve therapeutic access and adherence, particularly in Tier 2 and Tier 3 cities where Emcure has a robust footprint.
“We are proud to partner with Sanofi India to expand access to their trusted oral diabetes therapies,” said Satish Mehta, CEO & MD of Emcure Pharmaceuticals.
“This alliance aligns with our mission to offer comprehensive, high-quality diabetes care and improve health outcomes for millions across India.”
Also Read: Torrent Pharmaceuticals to Acquire JB Chemicals in INR 25689 Cr Deal from KKR
Scaling the Impact of Oral Anti-Diabetic Drugs
The deal strengthens Emcure’s diabetes portfolio and reinforces Sanofi’s focus on scaling the impact of its oral anti-diabetic drugs therapies.
Together, the companies are positioned to support better diabetes care across India’s vast and underserved regions.
